TAK1 inhibition in the DFG-out conformation

Chemical Biology and Drug Design

Volumn 82, Issue 5, 2013, Pages 500-505

  Kilty, Iain ^a,b   Green, Martin P ^a   Bell, Andrew S ^a   Brown, David G ^a   Dodd, Peter G ^a   Hewson, Christopher ^a   Hughes, Samantha J ^a   Phillips, Christopher ^a   Ryckmans, Thomas ^a   Smith, Robert T ^a   van Hoorn, Willem P ^a   Cohen, Philip ^c   Jones, Lyn H ^a,b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chemical biology; Drug design; Kinase; Phosphatase; Structure based drug design; X ray crystallography

Indexed keywords

ANTIINFLAMMATORY AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; HYDROGEN BOND; IC 50; NORMAL HUMAN; PRIORITY JOURNAL;

CHEMICAL BIOLOGY; DRUG DESIGN; KINASE; PHOSPHATASE; STRUCTURE-BASED DRUG DESIGN; X-RAY CRYSTALLOGRAPHY;

ANTI-INFLAMMATORY AGENTS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MAP KINASE KINASE KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885740180     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12169     Document Type: Article

References (33)

1. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J.-I., Cao Z., Matsumoto K. (1999) The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature;398:252-256.
2. Lee J.D., Mira-Arbibe L., Ulevitch R. (2000) TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol;68:909-915.
3. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J.-L., Chen Z.J. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature;412:346-351.
4. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T. et al. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol;6:1087-1095.
5. Gong Y.-N., Wang X., Wang J., Yang Z., Li S., Yang J. et al. (2010) Chemical probing reveals insights into the signaling mechanism of inflammasome activation. Cell Res;20:1289-1305.
6. Singh A., Sweeney M.F., Yu M., Burger A., Greninger P., Benes C. et al. (2012) TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell;148:639-650.
7. Ellestad G.A., Lovell F.M., Perkinson N.A., Hargreaves R.T., McGahren W.J. (1978) New zearalenone related macrolides and isocoumarins from an unidentified fungus. J Org Chem;43:2339-2343.
8. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M. et al. (2003) A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem;278:18485-18490.
9. Wu J., Powell F., Larsen N.A., Lai Z., Byth K.F., Read J. et al. (2013) Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem Biol;8:643-650.
10. Kamiyama H., Usui T., Sakurai H., Shoji M., Hayashi Y., Kakeya H. et al. (2008) Epoxyquinol B, a naturally occurring pentaketide dimer, inhibits NF-kB signaling by cross linking TAK1. Biosci Biotechnol Biochem;72:1894-1900.
11. Byth K., Palakurthi S., Yu L., Zhang Q. (2008) Methods for cancer treatment using TAK1 inhibitors. US Patent No. WO/2008/007072.
12. Lockman J.W., Reeder M.D., Robinson R., Ormonde P.A., Cimbora D.M., Williams B.L. et al. (2011) Oxindole derivatives as inhibitors of TAK1 kinase. Bioorg Med Chem Lett;21:1724-1727.
13. Kamiyama H., Kakeya H., Usui T., Nishikawa K., Shoji M., Hayashi Y. et al. (2008) Epoxyquinol B shows antiangiogenic and antitumor effects by inhibiting VEGFR2, EGFR, FGFR, and PDGFR. Oncol Res;17:11-21.
14. Brown K., Vial S.C.M., Dedi N., Long J.M., Dunster N.J., Cheetham G.M.T. (2005) Structural basis for the interaction of TAK1 kinase with its activating protein TAB 1. J Mol Biol;354:1013-1020.
15. Nishimura M., Shin M.-S., Singhirunnusorn P., Suzuki S., Kawanishi M., Koizumi K. et al. (2009) TAK1-mediated serine/threonine phosphorylation of epidermal growth factor receptor via p38/extracellular signal-regulated kinase: NF-κB-independent survival pathways in tumor necrosis factor alpha signaling. Mol Cell Biol;29:5529-5539.
16. Cheng T., Peng X.-C., Li F.-F., Zhang X.-L., Hu K.-Z., Zhu J.-F. et al. (2009) Transforming growth factor-β activated kinase 1 signaling pathways regulate TNF-α production by titanium alloy particles in RAW 264.7 cells. J Biomed Mater Res A;93A:1493-1499.
17. Schirmer A., Kennedy J., Murli S., Reid R., Santi D.V. (2006) Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc Natl Acad Sci USA;103:4234-4239.
18. Liu Q., Sabnis Y., Zhao Z., Zhang T., Buhrlage S.J., Jones L.H. et al. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol;20:146-159.
19. Jogireddy R., Dakas P.-Y., Valot G., Barluenga S., Winssinger N. (2009) Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases. Chem Eur J;15:11498-11506.
20. Cohen P. (2010) Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. Biochem J;425:53-54.
21. Bunnage M.E., Chekler E.L.P., Jones L.H. (2013) Target validation using chemical probes. Nat Chem Biol;9:195-199.
22. Xi H., Lunney E.A. (2011) The design, annotation, and application of a kinase-targeted library. Methods Mol Biol;685:279-291.
23. Millan D.S., Bunnage M.E., Burrows J.L., Butcher K.J., Dodd P.G., Evans T.J. et al. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem;54:7797-7814.
24. Rogers D., Hahn M. (2010) Extended-connectivity fingerprints. J Chem Inf Model;50:742-754.
25. van Hoorn W.P., Bell A.S. (2009) Searching chemical space with the Bayesian Idea Generator. J Chem Inf Model;49:2211-2220.
26. Lovering F., McDonald J., Whitlock G.A., Glossop P.A., Philips C., Bent A. et al. (2012) Identification of type-II inhibitors using kinase structures. Chem Biol Drug Des;80:657-664.
27. Zuccotto F., Ardini E., Casale E., Angiolini M. (2010) Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem;53:2681-2694.
28. Liu H., Kuhn C., Feru F., Jacques S.L., Deshmukh G.D., Ye P. et al. (2010) Enhanced selectivity profile of pyrazole-urea based DFG-out p38α inhibitors. Bioorg Med Chem Lett;20:4885-4891.
29. Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G. et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol;9:268-272.
30. Albaugh P., Fan Y., Mi Y., Sun F., Adrian F., Li N. et al. (2012) Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med Chem Lett;3:140-145.
31. Ikuta M., Kornienko M., Byrne N., Reid J.C., Mizuarai S., Kotani H. et al. (2007) Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: implications for the design of RSK1 specific inhibitors. Protein Sci;16:2626-2635.
32. Floersheimer A., Furet P., Manley P.W., Bold G., Boss E., Guagnano V. et al. (2003) Preparation of diarylurea derivatives useful for the treatment of protein kinase dependent diseases. Patent No. WO/2003/099771.
33. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H. et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J;408:297-315.